Inhibrx, Inc.

Sanofi 's shifting of R&D resources away from cancer to cement its industry leadership in immunology and inflammation is a sensible move but the company will continue to advance some interesting early

Merger-and-acquisition activity during the first quarter of 2024 was not likely to match the bustling pace of Q4 2023, when the aggregate dollar amount committed to acquisitions topped $52bn and nearl

Sanofi has hit the acquisition trail again to strengthen its rare disease pipeline, buying US biotech Inhibrx, Inc. and what it hopes will be a best-in-class asset to treat alpha-1 antitrypsin defi

Beam Therapeutics , a pioneer in the gene editing field of base editing, has unveiled early data from its first in vivo candidate, BEAM-302, which it hopes to take into the clinic next year. While m